Sakr et al. Diagnostic Pathology (2017) 12:71 DOI 10.1186/s13000-017-0661-0

RESEARCH

Open Access

cMYC expression in thyroid follicular cellderived carcinomas: a role in thyroid tumorigenesis Hany I. Sakr1, Deborah J. Chute1, Christian Nasr2 and Charles D. Sturgis1*

Abstract Background: cMYC regulates approximately 15% of human genes and is involved in up to 20% of all human cancers. Reports discussing cMYC protein expression in thyroid carcinomas are limited, with controversies pertaining to cMYC expression patterns noted in the literature. The aims of the current study were to clarify patterns and intensities of cMYC expression in follicular cell-derived thyroid carcinomas across a spectrum of cancer morphologies and disease aggressivities, to correlate cMYC with BRAFV600E expression, and to evaluate the potential role of cMYC in progression of well-differentiated thyroid carcinomas into less well-differentiated carcinomas. Methods: Immunohistochemical studies using specific monoclonal antibodies for cMYC and BRAFV600E were performed on tissue microarrays built from follicular cell-derived thyroid carcinomas (25 papillary, 24 follicular, 24 oncocytic variant of follicular, and 21 undifferentiated). In addition, cMYC IHC testing was also performed on whole tissue tumor sections from a subset of patients. Nodular hyperplasia cases were used as non-neoplastic controls. Appropriate positive and negative controls were included. Results: cMYC was expressed almost exclusively in a nuclear fashion in both thyroid carcinomas and nodular hyperplasias. cMYC expression was weakly positive in both nodular hyperplasias and well-differentiated carcinomas. The majority of undifferentiated carcinomas (UDCs) showed strong nuclear cMYC positivity. PTC cases that were positive for cMYC (6/25) harbored the BRAFV600E mutation. A correlation was confirmed between cMYC intensity and tumor size in UDCs. UDC cases that developed out of well-differentiated thyroid carcinomas showed frank overexpression of cMYC in the undifferentiated tumor components. Conclusions: Our study suggests that nuclear overexpression of cMYC correlates with tumorigenesis / dedifferentiation in follicular cell derived thyroid carcinomas, a concept that has not been shown before on whole tissue sections. Keywords: Thyroid carcinoma, cMYC, Immunohistochemistry, Tumorigenesis, Tissue microarray, Formalin-fixed, Paraffin-embedded

Background Thyroid cancer is the most common malignancy of the endocrine system. Approximately, 1.1% of men and women will be diagnosed with thyroid cancer at some point during their lifetimes [1]. Carcinomas derived from thyroid follicular epithelium comprise papillary, follicular, poorly differentiated, and undifferentiated (anaplastic) carcinomas. Understanding the molecular genetic alterations * Correspondence: [email protected] 1 Cleveland Clinic, Department of Pathology and Laboratory Medicine, 9500 Euclid Avenue, L25, Cleveland, OH 44195, USA Full list of author information is available at the end of the article

that drive thyroid carcinogenesis is important and may have prognostic and therapeutic implications, especially in poorly differentiated tumors. Some studies have linked certain oncogenes as well as tumor suppressor genes to the progression of well-differentiated thyroid carcinomas (papillary and follicular) into less differentiated ones (poorly differentiated and anaplastic) [2–6]. However, other studies have failed to show such correlations, questioning the tumor progression model that is well characterized in other organs systems [7, 8]. cMYC is a proto-oncogene located at chromosome 8q24.1. It encodes a nuclear phosphoprotein that acts as

© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Sakr et al. Diagnostic Pathology (2017) 12:71

Page 2 of 10

a growth promoter and a transcription factor. cMYC regulates approximately 15% of human genes and is estimated to be involved in 20% of all human cancers [9]. The available literature discussing cMYC expression in thyroid follicular cell-derived carcinomas focuses mainly on gene and/or mRNA expression levels [1–13]. Reports discussing cMYC protein expression in thyroid carcinomas are limited, and controversies exist pertaining to cMYC expression patterns (nuclear versus cytoplasmic immunoreactivity) in these tumors. Most authors report nuclear overexpression of cMYC to correlate with tumourigenesis; however, a few early studies also reported cytoplasmic expression (likely secondary to subcellular localization) [14–20]. Table 1 summarizes relevant IHC studies detailing cMYC expression in thyroid follicular cell-derived carcinomas [14–18, 21–24]. Herein, we utilized IHC for cMYC in a tissue microarray (TMA) study performed on a spectrum of follicular cell-derived thyroid carcinomas, including papillary (n = 25), follicular (n = 25), oncocytic variant of follicular (n = 25), and undifferentiated (n = 22) carcinomas. Twenty five cases of thyroid nodular hyperplasia were also included in the TMA as non-neoplastic controls. Aims of this study were to further clarify patterns of cMYC expression in thyroid carcinomas across the spectrum of morphology and disease aggressivity, to evaluate potential cMYC diagnostic usefulness, to find a correlation (if any) between cMYC and BRAF V600E expression in thyroid carcinomas, and to determine the extent to which cMYC may contribute to carcinogenesis.

Methods Patient selection

The Cleveland Clinic anatomic pathology archives were reviewed to identify patients diagnosed with thyroid follicular cell-derived carcinomas. A spectrum of carcinoma cases was selected from archival material. The study set included 25 cases of papillary thyroid carcinoma (PTC), as appearing consecutively in the retrieval, and including cases with follicular, classical, oncocytic and tall cell features (2011 archive). In addition, 25 consecutive cases of follicular thyroid carcinoma (FC) (2004-2014 archive), and 25 consecutive cases of the oncocytic variant of follicular carcinoma (OvFC) (20052014 archive) were retrieved. The archive was searched for the period from 2004 to 2014 and only 22 consecutive cases of undifferentiated carcinoma (UDC) were found. In addition, 25 cases of nodular hyperplasia (NH) were included as controls (2011 archive). We did not include poorly differentiated carcinomas (PDC) in our TMA study as our data retrieval did not provide enough pure cases to allow for pair-wise correlations with the number of cases in the other diagnostic categories. The majority of poorly differentiated carcinomas in our archive existed as focal areas of disease in backgrounds of better differentiated carcinomas, and did not lend themselves as readily to study by TMA as undifferentiated tumors with large (whole tissue block) areas of anaplastic malignancy. Clinical details were obtained from patients’ pathology reports and original electronic medical records. The morphologic features, histopathologic variants, and the

Table 1 Summary of cMYC expression studies (using IHC) in thyroid follicular cell-derived carcinomas PTC (% Sn, n)

FC (% Sn, n)

OvFC (% Sn, n)

UDC (% Sn, n)

Staining pattern

Ref.

TB

100 (27)

100 (5)

ND

ND

C

Mizukami et al.,20 1991a

TMA

?? (44)

?? (35)

ND

?? (11)

C, Nb

Braunschweig et al.,21 2007

ND

100 (6)

C

Hashimoto et al.,22 1990

ND

C

Auguste et al.,23 1992c

Tissue Studied Polyclonal antibody

Monoclonal antibody TB

90 (39)

67 (16)

TB

ND

45 (20)

TB

ND

17 (12)

100 (8)

ND

C

Masood et al.,24 1993

TB

100 (19)

100 (4)

ND

100 (2)

N

Haugen et al.,27 1993d

TB

ND

ND

ND

59 (22)

N

Kurihara et al.,28 2004

TMA

66 (167)

ND

ND

ND

N

Lee et al.,29 2012e

TB

81 (58)

ND

ND

ND

N

Hu et al.,30 2015

The biomarkers are arranged according to the type of antibody used; polyclonal followed by monoclonal. For each histologic type of thyroid follicular cell-derived carcinoma, the sensitivity of the biomarker studied is documented first (indicated by % of immunoreactivity reported in the study) followed by the total number of cases studied. Any percentage with decimal ≥0.5 is rounded up to 1, otherwise rounded down a cMYC immunoreactivity was variable in PTC and FC. The antibody used showed immunoreactivity in all follicular adenomas and Grave’s disease cases tested as well b Antibody’s immunoreactivity signals were quantified digitally using P-SCAN software c The 20 cases included FC and OvFC without clear distinction d cMYC immunoreactivity was weak in FC and 50% of PTC cases. The antibody also showed immunoreactivity in all follicular adenomas and Grave’s disease cases e cMYC immunoreactivity was variable IHC immunohistochemistry, NH nodular hyperplasia, PTC papillary thyroid carcinoma, FC follicular carcinoma, OvFC oncocytic variant of follicular carcinoma, UDC undifferentiated carcinoma, TB tissue blocks, TMA tissue microarray, ND not done, Sn sensitivity, C cytoplasmic, N nuclear

Sakr et al. Diagnostic Pathology (2017) 12:71

extent of tumor at time of diagnosis (pT) were classified according to World Health Organization (WHO) criteria and American Joint Committee on Cancer (AJCC) parameters [25, 26]. Thirteen UDC cases (59% of 22) were documented to be associated with either concomitant (11/13) or pre-existing (2/13) well differentiated thyroid carcinomas [11/13 (85%) PTC, and 2/13 (15%) OvFC] either by surgical pathology or fine needle aspiration cytopathology examination. All aspects of this study were approved by the Cleveland Clinic Institutional Review Board under protocol # 16-099 (project approval date 01/24/2016). Ethical practices were followed throughout. Tissue microarray

Thyroid tissue microarrays (TMAs) were constructed from original formalin-fixed, paraffin-embedded (FFPE) tissue blocks, as previously described [27]. In brief, regular 5-μm sections were made and stained with Hematoxylin and Eosin (H&E) to confirm previously rendered histologic diagnoses based upon current WHO classification [25]. Selected areas were marked on the H&E stained slides as a guide for TMA construction by one pathologist (CS). Focused areas from the central region of each submitted tumor were identified for inclusion in the array based upon histology being representative of the entire lesion, tissue being representative of well-fixed regions of the paraffin blocks, and tumor tissue viability (excluding areas of necrosis). Focused areas of benign thyroid tissue taken from between hyperplastic / adenomatoid nodules were selected as control cores in the cases of nodular hyperplasia. Tissue cylinders with a diameter of 1.2 mm were punched from each donor tissue block and brought into the recipient paraffin block using “Pathology Devices TMArrayer” (Pathology Devices Inc., Westminster, MD). Two cores from each case i.e. NH or thyroid follicular cell-derived carcinomas were arrayed with 1.8 mm spacing. A total of three TMAs were created; TMA1 included the NH and PTC cases, TMA2 housed the FC and OvFC cases, and TMA3 had the UDC cases. The first core of each TMA was made from normal liver tissue to allow proper orientation by the scoring pathologists. Slides were cut and stained with H&E to ensure that the all of the desired tissue cores were present. Immunohistochemistry

Immunohistochemistry (IHC) staining for cMYC was performed on the Ventana Benchmark Ultra automated immunostainer (Ventana Medical Systems (VMS), Tucson AZ). Formalin-fixed, paraffin-embedded TMA sections as well as selected whole tissue sections [from UDC cases that had concomitant well differentiated carcinomas (10) or PTC preexisting UDC (1)] were cut at 4 μm. Sections were treated with online deparaffinization, followed by

Page 3 of 10

online epitope retrieval using a high pH Tris-based solution (VMS Ultra CC1) for 64 min at 100 °C. The slides were incubated with the anti-cMYC primary antibody [rabbit monoclonal primary antibody (Y69), Abcam (Cambridge, MA)] prediluted to 1: 50 for 32 min with no heat. Localization of the antigen-antibody complex was achieved using the VMS OptiView DAB detection kit (biotin-free polymer system). The complex is visualized with hydrogen peroxide substrate and diaminobenzidine tetrahydrochloride (DAB) chromogen. Appropriate positive and negative controls were included. For BRAFV600E mutation, IHC staining was performed on formalin-fixed, paraffin-embedded tissues cut in 4 μm sections on the Ventana Benchmark Ultra automated immunostainer (VMS, Tucson AZ). Online deparaffinization was followed by online epitope retrieval using “VMS Ultra CC1” solution for 64 min at 100 °C. The slides were incubated with the anti-BRAF V600E primary antibody [mouse monoclonal (VE1), Spring Bioscience, Pleasanton CA] at 1:175 dilution for 16 min at 37 °C. Localization of the antigen-antibody complex was achieved using the VMS OptiView DAB detection kit and VMS OptiView Amplification kit. Appropriate positive and negative controls were included. Evaluation of the pattern of immunoreactivity, percentage of cells staining, and staining intensities for cMYC and BRAFV600E were performed by two independent pathologists (HS & CS). Scoring systems for proportion of positive cells and staining intensity were adapted from previously published investigations [21, 22, 24]. The percentage of cells staining was graded on a scale of 1–4 [1 = 10–24%; 2 = 25– 49%; 3 = 50–74%; and 4 = ≥ 75%]. For cMYC, the expression was almost exclusively seen in a nuclear fashion in both thyroid carcinomas and nodular hyperplasias. The cut off for a negative result was ≤9% cell staining. Staining intensity was scored on a scale of +1 to +3 [+1 = weak, +2 = intermediate, +3 = strong]. Both percentage of cells staining and intensities of staining were used to define weakly versus strongly positive cMYC cases as well as to set a cutoff for BRAF positivity. Weakly positive cases cMYC cases were those with ≥1 (percentage scale) and +1 (intensity scale) reading, and strongly positive cases were those with ≥1 (percentage scale) and ≥ + 2 (intensity scale). For BRAF, the expression was almost exclusively seen in a cytoplasmic, granular fashion in thyroid carcinomas. Positive cases were defined as ≥3 (percentage scale) and ≥ + 1 (intensity scale). Discrepant pattern, percentage and intensity results were resolved by simultaneous dual-headed microscope review and consensus agreement of the two independent pathologists. Statistical analysis

Comparison of distributions of clinicopathologic variables among different histologies in the study was performed

Sakr et al. Diagnostic Pathology (2017) 12:71

Page 4 of 10

using two-tailed Student’s t test (Microsoft Excel, 2010, Seattle, WA) for continuous variables (e.g. age), and Fisher’s exact test (GraphPad Prism software, GraphPad, La Jolla, CA) for categorical variables (e.g. gender). Mean values of cMYC expression were compared using twotailed Student’s t tests. Comparison of distributions of cMYC expression among all histologic types was performed by an exact Kruskal-Wallis test. Pairwise comparisons of distributions of cMYC expression among pairs of histologies, as well as clinicopathologic variables (e.g. age, tumor size) for each histologic type of thyroid carcinoma were performed by an exact Mann-Whitney test (unless otherwise specified). P values 25% cells staining weakly for cMYC (scores 2 & +1, respectively), FC had a score of 2 & +2, OvFC had 3 & +2 score and UDC showed diffuse, mostly strong staining with a score of 4 & +3

Table 3 cMYC nuclear expression in nodular hyperplasias and follicular cell-derived carcinomas cMYC expression

NH (n = 25)

PTC (n = 25)

FC (n = 24)a

OvFC (n = 24)b

UDC (n = 21)c

Negative

12

19

18

12

5

Weak positive

11

5

5

7

4

Strong positive

2

1

1

5

12

Total positive

13

6

6

12

16

P value total positives (UDC vs other)

0.13

0.0009

0.0009

0.12

P value strong positives (UDC vs other)

0.0004

0.0001

0.0001

0.02

cMYC nuclear expression was compared between different groups, as shown above using Fisher’s exact test. a, b, c One case was excluded from each of the FC, OvFC, and UDC categories secondary to TMA tissue loss NH nodular hyperplasia, PTC papillary thyroid carcinoma, FC follicular carcinoma, OvFC oncocytic variant of follicular carcinoma, UDC undifferentiated carcinoma Statistically significant P values are in bold

moderate cMYC intensity. Unlike the other thyroid carcinomas, UDC showed the greatest number of cases with strong cMYC intensity (+2 and +3). In addition, UDC was the only histologic type to show strong (+3) nuclear cMYC intensity. Comparison of the distributions of cMYC expression among tumor histologies showed a statistically significantly difference (p < 0.0001). Three pairwise comparisons between UDC and other tumor histologies were performed to determine the histologies in which significant differences in distributions of cMYC expression existed. UDC showed significantly higher cMYC expression than all other carcinoma types (PTC, FC, and OvFC) (all p < 0.005). cMYC Immunostaining and clinical data

cMYC expression was stratified in the carcinoma groups according to pathologic tumor staging “pT”, as defined by AJCC parameters. Given the small number of cases per group and the uneven distribution of pT stages in each group, no statistically significant correlations were demonstrated between cMYC expression and stage. For well differentiated types of thyroid carcinomas (PTC,

Sakr et al. Diagnostic Pathology (2017) 12:71

Page 6 of 10

Fig. 2 cMYC overexpression in a UDC developing out of a PTC (representative whole slide images). cMYC nuclear overexpression as seen in one of the UDC cases concomitantly developing out of a PTC. The PTC case showed >25% cells staining weakly for cMYC (scores 2 & +1, respectively) with UDC developing in vicinity showing 3 & +2 score. H&E background photomicrographs were originally taken at 20× magnification, and the cMYC IHC inserts were taken at 60X magnification

FC, and OvFC), there was a non-significant trend toward lower cMYC expression from stages pT1 through pT3. Of note, a trend toward somewhat different cMYC staining was noted in the higher stage OvFC cases (pT3 and pT4). In the pT3 cases there was 40% (4/10) cMYC positivity, all of which was weak positivity. In contrast, the two pT4- OvFC cases showed strong cMYC positivity. Of note, patients with UDC > 20 mm had statistically significant higher cMYC intensities than those with smaller tumors (< 20 mm). In addition, 62% of UDC cases (8/13) that had a well-differentiated precursor lesion stained positive for cMYC. No significant differences in cMYC expression were found in any of the tumor types when comparisons with patient ages, or tumor sizes (other than UDC) were performed [Exact Mann Whitney]. Immunohistochemistry for BRAF

V600E

mutation

BRAFV600E mutation was assessed in 96 follicular cellderived thyroid carcinomas from 96 separate patients using an anti- BRAFV600E mouse monoclonal antibody (VE1). Only PTC and UDC showed significant numbers of BRAFV600E mutation positive cases, 15/25 (60%) for PTC and 11/21 (52%) for UDC, respectively (Table 4). Historical PCR results [224 base pair product including codon 600 with exon 15, Applied Biosystems; Foster City, CA] had previously confirmed 6 of 14 PTC cases positive for mutation. All PCR BRAF mutant cases were confirmed positive by TMA IHC. Only one case of

OvFC showed the BRAFV600E mutation. No BRAFV600E mutation was detected in NH or FC cases. The relationship between cMYC expression and BRAFV600E mutation status in PTC and UDC cases were independently examined. All the PTC cases that stained for cMYC by IHC harbored the BRAFV600E mutation (n = 6), which represented 40% of all BRAFV600E mutation positive PTC cases (6/15). No cMYC IHC staining was documented in BRAFwt cases. For UDC cases, cMYC expression was distributed almost equally between UDC cases regardless of BRAF mutation status; 8/11 in BRAFV600E mutation positive cases vs. 8/10 in BRAFwt cases. Table 4 BRAFV600E expression in thyroid nodular hyperplasias and follicular cell-derived carcinomas BRAFV600E expression

NH PTC FC OvFC UDC (n = 25) (n = 25) (n = 25) (n = 25) (n = 21)d

Positive

0

15

0

1

11

Negative

25

10

25

24

10

0.0001

1

1

0.0004

P value (PTC vs. other)

0.0001

0.0001

0.77

P valuec (UDC vs. other)

0.0001

0.0004

P valuea (NH vs. other) b

BRAFV600E expression was compared between different groups, as shown above (a NH versus thyroid carcinomas, b PTC versus other thyroid carcinomas, c UDC versus FC and OC), using Fisher’s exact test. d One case was excluded from UDC category secondary to TMA tissue loss NH nodular hyperplasia, PTC papillary thyroid carcinoma, FC follicular carcinoma, OvFC oncocytic variant of follicular carcinoma, UDC undifferentiated carcinoma Statistically significant P values are in bold

Sakr et al. Diagnostic Pathology (2017) 12:71

Discussion Herein, we conducted an extensive literature review for relevant IHC characterization studies performed since 1990 for cMYC protein expression in thyroid follicular cell-derived carcinomas. Some disparities regarding cMYC expression (staining patterns, sensitivities, and/or intensities) in thyroid follicular cell-derived carcinomas were noted in these references (see Table 1 for details). Studies have shown nuclear (mostly) and cytoplasmic (occasionally) expression patterns for cMYC. Of note, older studies failed to show nuclear IHC immunoreactivity for cMYC [14, 16–18]. It is well known that cMYC exerts its oncogenic potential through transcriptional deregulation, mostly activation, of many downstream genes which are involved in cellular proliferation, differentiation, and apoptosis [28–30]. Though several cMYC variants have been previously identified, most of them retain the nuclear localization signal (NLS) [31, 32]. Interestingly, there have been reports of cytoplasmic localization of cMYC, mostly in differentiated cells [33, 34]. Studies published for cytoplasmic cMYC expression in tumors have shown discordance pertaining to cMYC localization among histologic patterns of non-neoplastic and neoplastic tissues [35, 36]. Similar to our findings, these studies relied upon immunohistochemical evaluation without cMYC protein characterization. Some authors have suggested that a truncated cMYC isoform that is localized to the cytoplasm has no detectable effect on cell proliferation or survival [32]. Studies investigating cMYC expression in UDC are very limited. The only study with sizeable numbers of patients (number of cases, n = 22) showed 59% cMYC immunoreactivity, less than the 76% shown in our study. This manuscript did not comment on staining intensity [22]. Using a specific cMYC monoclonal antibody (Y69, rabbit monoclonal, Abcam), we confirmed, almost exclusively, a nuclear staining pattern for cMYC in thyroid follicular cell derived tumors. Contrary to previous studies (Table 1), results of cMYC expression in well differentiated carcinomas appear different with fewer positive cases in our work. Interestingly, cMYC expression was found to be significantly higher in UDC compared to nodular hyperplasias and well-differentiated carcinomas (PTC/FC/ OvFC) [all p < 0.05]. The sensitivity of the anti-cMYC monoclonal antibody used in the current study appears higher than that of the antibodies used previously. In the current study, the clinicopathologic data showed that 13 out of 22 UDC cases had precursor well-differentiated thyroid carcinomas, 62% of them (8/ 13) exhibited nuclear cMYC expression. Interestingly, 50% of the cMYC positive cases in UDC group (8/16) did not have any associated precursor lesion per pathology reports. Our data showed that undifferentiated

Page 7 of 10

carcinomas larger than 20 mm showed higher cMYC intensities (≥1+). A finding such as this has not been previously reported. In the current study we used TMA for cMYC IHC staining. One concern that may arise is that UDCs may show heterogeneous protein expression levels in various areas of a single neoplasm. To overcome that problem and to elucidate a role of cMYC in thyroid tumorigenesis, we stained whole tissue sections from a subset of the 13 UDC cases that were documented to have either concomitant (10/13) or precursor (1/13) well-differentiated thyroid carcinomas. The results of cMYC IHC staining were informative and emphasize the importance of adequate tissue sampling in molecular studies. Those 11 cases included 9 PTC cases (with only 7 UDC component represented on the same tissue section) and 2 OvFC cases. In a sharp contrast to the PTC group (25 cases) in the TMA, almost all PTC cases (8/9) whether classic (5/9) or with tall cell features (3/9) that developed into UDC showed stronger and more diffuse cMYC expression. Only one case of PTC, follicular variant, did not show cMYC expression (1/9). Interestingly, the two OvFC cases preexisting UDC did not show cMYC expression. The UDC component associated with preexisting PTC (7 cases) showed cMYC overexpression in 100% of the cases and in one case (1/2) associated with preexisting OvFC. In addition, the pattern and intensity of cMYC expression for UDC in whole tissue sections was similar to that interpreted from the TMA cores. BRAFV600E mutation has been reported to occur almost exclusively in PTC and PTC-derived UDC, while BRAFV600E mutations are known to be uncommon in FC and other types of thyroid carcinomas [3, 37]. We investigated the correlation between cMYC expression and BRAF status in PTC and UDC cases using a specific BRAFV600E mutation monoclonal antibody. Our findings are similar to what have been previously published in the literature regarding BRAFV600E mutation in thyroid follicular cell-derived carcinomas. We found BRAFV600E to be expressed almost exclusively in PTC and UDC cases. In our study, more than half of the BRAFV600E positive UDCs with preceding or concomitant well differentiated carcinomas showed diffuse, nuclear cMYC overexpression. We did not demonstrate a linear correlation between BRAFV600E mutation and cMYC expression in UDC cases, either in those cases that seemed to arise in association with well differentiated carcinoma or in those that appeared de novo. Interestingly, all cases of PTC that were weakly positive for cMYC (6/25) harbored the BRAFV600E mutation. A recent manuscript based upon multiplatform ‘omics’ molecular analysis of nearly 500 PTCs from The Cancer Genome Atlas (TCGA) Research Network categorized PTCs into two broad categories, a well differentiated RAS-like (RL) type with predominance of follicular

Sakr et al. Diagnostic Pathology (2017) 12:71

variant histology, and a more heterogeneous, less differentiated BRAFV600E-like (BVL) type with classic and tall cell features [38]. In light of the TCGA study results, it could be inferred that some UDCs with preceding or concomitant PTCs could possess antecedent BRAFV600E mutations either prior to or simultaneously with cMYC overexpression, the latter of which appears uniformly present in UDCs on our data. Further investigations of relationships between BRAFV600E and cMYC in UDCs using refined molecular techniques and larger cohorts (samples from multiple institutions) are recommended. Prior studies have analyzed PDC and UDC via next generation sequencing (NGS) to characterize genomic and/or transcriptomic landscape for these aggressive entities. Multiple candidate genes involved in signal transduction, cell cycle regulation, and DNA repair had been identified e.g. EGFR, ATM, and TP53 [39, 40]. Noticeably, wide genomic analysis of variable numbers of UDC cases have failed to show mutations in cMYC. Prior reports based upon both thyroid cancer cell lines and animal model studies have suggested that cMYC plays a role in thyroid carcinogenesis and progression from well- to less-differentiated carcinomas [41, 42]. It is postulated that cMYC gene deregulations themselves (e.g. translocations or amplifications) are not the sole mechanisms for cMYC overexpression and subsequent thyroid carcinoma progression [13, 43]. It seems likely that other pathways / factors are associated with the increased mRNA levels and levels of MYC protein expression which have been documented to occur with increasing histologic aggressiveness and dedifferentiation in thyroid carcinomas [43, 44]. In our study, there was a concomitant expression/overexpression of cMYC in well differentiated thyroid carcinomas that developed into UDC. The overexpression of cMYC in UDC cases suggests a role for cMYC in the multi-stage process of carcinogenesis. Based on our findings, extensive tissue sampling with adequate representation for cMYC IHC staining in cases of PTC is recommended. In association with other mutations known to occur in UDC e.g. EGFR, ATM, or TP53, cMYC may be a potential biomarker useful for diagnostic work up of well differentiated thyroid carcinomas with aggressive features. Inclusion of poorly differentiated carcinomas in additional studies might provide additional insight at an intermediate stage along the spectrum of disease differentiation.

Conclusions In summary, we demonstrated a nuclear staining pattern of cMYC IHC in TMAs of follicular cell-derived thyroid carcinomas. cMYC expression in undifferentiated thyroid carcinomas was statistically significantly greater than in NH and well-differentiated carcinomas. cMYC positivity was identified in UDC cases (16/21, 76%) with

Page 8 of 10

strong positivity in more than half (57%) of all UDC cases. In addition, UDC cases that developed in association with or out of well-differentiated thyroid carcinomas showed frank overexpression of cMYC upon dedifferentiation. These findings might suggest a possible role for cMYC in thyroid carcinogenesis and dedifferentiation, a concept that is supported by both TMA and whole tissue section IHC in the current investigation. Additional specific next generation sequencing testing and / or mRNA studies of cMYC could prove valuable; however, such testing is beyond the scope of our investigations. UDC is an aggressive disease with limited therapeutic options and uniformly dismal associated clinical outcomes. Based upon our results, clinical trials of targeted anti-cMYC therapies might be considered in patients with UDC whose tumors can be demonstrated to express cMYC by IHC. Clinical trials with targeted anti-MYC therapies might provide additional avenues for therapy to UDC patients with limited therapeutic options. Abbreviations FC: Follicular carcinoma; FFPE: Formalin-fixed, paraffin-embedded; IHC: Immunohistochemistry; NH: Nodular hyperplasia; OvFC: Oncocytic variant of FC; PTC: Papillary thyroid carcinoma; TMA: Tissue microarray; UDC: Undifferentiated carcinoma Acknowledgements The authors would like to thank Jyoti Harwalkar, Christopher Lanigan, Jennifer Coleman, and Bonnie Shadrach for their excellent technical support. No external funding sources are relevant to this submission. Funding No external funding sources are relevant to this submission. Availability of data and materials The datasets generated during the current study are available from the corresponding author on reasonable request. Authors’ contributions HIS and CDS performed the research and wrote the paper. HIS analyzed the data. CDS and DJC assisted with data analysis and interpretation. DJC and CN read and revised the paper, and agreed with the final version of the paper. All authors read and approved the final manuscript. Ethics approval and consent to participate All aspects of this study were approved by the Cleveland Clinic Institutional Review Board under protocol # 16-099 (project approval date 01/24/2016). Ethical practices were followed throughout. Patients’ consents were not needed per our IRB approval for this retrospective study. Consent for publication Not applicable. Competing interests The authors declare that they have no competing interests.

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Author details 1 Cleveland Clinic, Department of Pathology and Laboratory Medicine, 9500 Euclid Avenue, L25, Cleveland, OH 44195, USA. 2Cleveland Clinic, Department of Endocrinology, Diabetes and Metabolism, Cleveland, USA.

Sakr et al. Diagnostic Pathology (2017) 12:71

Received: 23 June 2017 Accepted: 25 September 2017

References 1. National Cancer Institute. SEER Stat Fact Sheets: thyroid cancer. http://seer. cancer.gov/statfacts/html/thyro.html. Accessed September 11, 2016. 2. Nikiforova MN, Kimura ET, Gandhi M, Biddinger PW, Knauf JA, Basolo F, Zhu Z, Giannini R, Salvatore G, Fusco A, Santoro M, Fagin JA, Nikiforov YE. BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab. 2003;88(11):5399–404. 3. Saltman B, Singh B, Hedvat CV, Wreesmann VB, Ghossein R. Patterns of expression of cell cycle/apoptosis genes along the spectrum of thyroid carcinoma progression. Surgery. 2006;140(6):899–905. 4. Wiseman SM, Masoudi H, Niblock P, Turbin D, Rajput A, Hay J, Bugis S, Filipenko D, Huntsman D, Gilks B. Anaplastic thyroid carcinoma: expression profile of targets for therapy offers new insights for disease treatment. Ann Surg Oncol. 2007;14(2):719–29. 5. Soares P, Lima J, Preto A, Castro P, Vinagre J, Celestino R, Couto JP, Prazeres H, Eloy C, Máximo V, Sobrinho-Simões M. Genetic alterations in poorly differentiated and undifferentiated thyroid carcinomas. Curr Genomics. 2011;12(8):609–17. 6. Smith N, Nucera C. Personalized therapy in patients with anaplastic thyroid cancer: targeting genetic and epigenetic alterations. J Clin Endocrinol Metab. 2015;100(1):35–42. 7. Tallini G, Santoro M, Helie M, Carlomagno F, Salvatore G, Chiappetta G, Carcangiu L, Fusco A. RET/PTC oncogene activation defines a subset of papillary thyroid carcinomas lacking evidence of progression to poorly differentiated or undifferentiated tumor phenotypes. Clin Cancer Res. 1998;4(2):287–94. 8. Puxeddu E, Moretti S, Elisei R, Romei C, Pascucci R, Martinelli M, Marino C, Avenia N, Rossi ED, Fadda G, Cavaliere A, Ribacchi R, Falorni A, Pontecorvi A. BRAFV599E mutation is the leading genetic event in adult sporadic papillary thyroid carcinomas. J Clin Endocrinol Metab. 2004;89(5):2414–20. 9. Dang CV, O'Donnell KA, Zeller KI, Nguyen T, Osthus RC, Li F. The cMYC target gene network. Semin Cancer Biol. 2006;16(4):253–64. 10. Terrier P, Sheng ZM, Schlumberger M, Tubiana M, Caillou B, Travagli JP, Fragu P, Parmentier C, Riou G. Structure and expression of cMYC and c-fos proto-oncogenes in thyroid carcinomas. Br J Cancer. 1988;57(1):43–7. 11. Wyllie FS, Lemoine NR, Williams ED, Wynford-Thomas D. Structure and expression of nuclear oncogenes in multi-stage thyroid tumourigenesis. Br J Cancer. 1989;60(4):561–5. 12. Hemmer S, Wasenius VM, Knuutila S, Franssila K, Joensuu H. DNA copy number changes in thyroid carcinoma. Am J Pathol. 1999;154(5):1539–47. 13. Bièche I, Franc B, Vidaud D, Vidaud M, Lidereau R. Analyses of MYC, ERBB2, and CCND1 genes in benign and malignant thyroid follicular cell tumors by real-time polymerase chain reaction. Thyroid. 2001;11(2):147–52. 14. Mizukami Y, Nonomura A, Hashimoto T, Michigishi T, Noguchi M, Matsubara F, Yanaihara N. Immunohistochemical demonstration of epidermal growth factor and cMYC oncogene product in normal, benign and malignant thyroid tissues. Histopathology. 1991;18(1):11–8. 15. Braunschweig T, Kaserer K, Chung JY, Bilke S, Krizman D, Knezevic V, Hewitt SM. Proteomic expression profiling of thyroid neoplasms. Proteomics Clin Appl. 2007;1(3):264–71. 16. Hashimoto T, Matsubara F, Mizukami Y, Miyazaki I, Michigishi T, Yanaihara N. Tumor markers and oncogene expression in thyroid cancer using biochemical and immunohistochemical studies. Endocrinol Jpn. 1990;37(2):247–54. 17. Auguste LJ, Masood S, Westerband A, Belluco C, Valderamma E, Attie J. Oncogene expression in follicular neoplasms of the thyroid. Am J Surg. 1992;164(6):592–3. 18. Masood S, Auguste LJ, Westerband A, Belluco C, Valderama E, Attie J. Differential oncogenic expression in thyroid follicular and Hürthle cell carcinomas. Am J Surg. 1993;166(4):366–8. 19. Khaleghian M, Jahanzad I, Shakoori A, Razavi AE, Azimi C. Association between amplification and expression of cmyc gene and clinicopathological characteristics of stomach cancer. Iran Red Crescent Med J. 2016;18(2):e21221. 20. Udager AM, DeMarzo AM, Shi Y, Hicks JL, Cao X, Siddiqui J, Jiang H, Chinnaiyan AM, Mehra R. Concurrent nuclear erg and myc protein overexpression defines a subset of locally advanced prostate cancer: potential opportunities for synergistic targeted therapeutics. Prostate. 2016;76(9):845–53.

Page 9 of 10

21. Haugen DR, Akslen LA, Varhaug JE, Lillehaug JR. Demonstration of a TGFalpha-EGF-receptor autocrine loop and cMYC protein over-expression in papillary thyroid carcinomas. Int J Cancer. 1933;55(1):37–43. 22. Kurihara T, Ikeda S, Ishizaki Y, Fujimori M, Tokumoto N, Hirata Y, Ozaki S, Okajima M, Sugino K, Asahara T. Immunohistochemical and sequencing analyses of the wnt signaling components in Japanese anaplastic thyroid cancers. Thyroid. 2004;14(12):1020–9. 23. Lee JU, Huang S, Lee MH, Lee SE, Ryu MJ, Kim SJ, Kim YK, Kim SY, Joung KH, Kim JM, Shong M, Jo YS. Dual specificity phosphatase 6 as a predictor of invasiveness in papillary thyroid cancer. Eur J Endocrinol. 2012;167(1):93–101. 24. Hu YJ, Luo XY, Yang Y, Chen CY, Zhang ZY, Guo X. Characterization and significance of MUC1 and cMYC expression in elderly patients with papillary thyroid carcinoma. Genet Mol Res. 2015;14(4):15325–30. 25. DeLellis RA, Lioyd RV, Heitz PU, Eng C. Tumors of thyroid and parathyroid. in world health organization classification of tumours pathology and genetics tumors of endocrine organs. Lyon: IARC press. 2008:49–80. 26. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A. AJCC Cancer Staging Manual. 7th ed. France: Springer; 2010. p. 87–96. 27. Kononen J, Bubendorf L, Kallioniemi A, Bärlund M, Schraml P, Leighton S, Torhorst J, Mihatsch MJ, Sauter G, Kallioniemi OP. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med. 1998;4(7):844–7. 28. Li Z, Van Calcar S, Qu C, Cavenee WK, Zhang MQ, Ren B. A global transcriptional regulatory role for cMYC in Burkitt’s lymphoma cells. Proc Natl Acad Sci U S A. 2003;100:8164–9. 29. Marinkovic D, Marinkovic T, Kokai E, Barth T, Möller P, Wirth T. Identification of novel Myc target genes with a potential role in lymphomagenesis. Nucleic Acids Res. 2004;32:5368–78. 30. Zeng W, Sun H, Meng F, Liu Z, Xiong J, Zhou S, Li F, Hu J, Hu Z, Liu Z. Nuclear C-MYC expression level is associated with disease progression and potentially predictive of two year overall survival in prostate cancer. Int J Clin Exp Pathol. 2015;8(2):1878–88. 31. Gregory MA, Qi Y, Hann SR. Phosphorylation by glycogen synthase kinase-3 controls cMYC Proteolysis and subnuclear localization. J Biol Chem. 2003;278(51):51606–12. 32. Conacci-Sorrell M, Ngouenet C, Eisenman RN. Myc-nick: a cytoplasmic cleavage product of Myc that promotes α-tubulin acetylation and cell differentiation. Cell. 2010;142(3):480–93. 33. Wakamatsu Y, Watanabe Y, Shimono A, Kondoh H. Transition of localization of the N-Myc protein from nucleus to cytoplasm in differentiating neurons. Neuron. 1993;10:1–9. 34. Okano HJ, Park WY, Corradi JP, Darnell RB. The cytoplasmic Purkinje onconeural antigen cdr2 down-regulates cMYC function: implications for neuronal and tumor cell survival. Genes Dev. 1999;13:2087–97. 35. Bai MK, Costopoulos JS, Christoforidou BP, Papadimitriou CS. Immunohistochemical detection of the cMYC oncogene product in normal, hyperplastic and carcinomatous endometrium. Oncology. 1994;51:314–9. 36. Pietiläinen T, Lipponen P, Aaltomaa S, Eskelinen M, Kosma VM, Syrjänen K. Expression of cMYC proteins in breast cancer as related to established prognostic factors and survival. Anticancer Res. 1995;15:959–64. 37. Sinno S, Choucair M, Nasrallah M, Wadi L, Jabbour MN, Nassif S. Activating BRAF mutations detected in mixed hürthle cell carcinoma and multifocal papillary carcinoma of the thyroid gland: report of an unusual case and review of the literature. Int J Surg Pathol. 2016;24: 519–24. 38. The Cancer Genome Atlas Research Network. Integrated genomic characterization of papillary thyroid carcinoma. Cell. 2014;159:676–90. 39. Landa I, Ibrahimpasic T, Boucai L, Sinha R, Knauf JA, Shah RH, Dogan S, Ricarte-Filho JC, Krishnamoorthy GP, Xu B, Schultz N, Berger MF, Sander C, Taylor BS, Ghossein R, Ganly I, Fagin JA. Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers. J Clin Invest. 2016;126(3):1052–66. 40. Jeon MJ, Chun SM, Kim D, Kwon H, Jang EK, Kim TY, Kim WB, Shong YK, Jang SJ, Song DE, Kim WG. Genomic alterations of anaplastic thyroid carcinoma detected by targeted massive parallel sequencing in a BRAFV600E mutation-prevalent area. Thyroid. 2016;26(5):683–90. 41. Cerutti J, Trapasso F, Battaglia C, Zhang L, Martelli ML, Visconti R, Berlingieri MT, Fagin JA, Santoro M, Fusco A. Block of cMYC expression by antisense oligonucleotides inhibits proliferation of human thyroid carcinoma cell lines. Clin Cancer Res. 1996;2(1):119–26.

Sakr et al. Diagnostic Pathology (2017) 12:71

Page 10 of 10

42. Zhu X, Zhao L, Park JW, Willingham MC, Cheng SY. Synergistic signaling of KRAS and thyroid hormone receptor β mutants promotes undifferentiated thyroid cancer through MYC up-regulation. Neoplasia. 2014;16(9):757–69. 43. Várkondi E, Gyory F, Nagy A, Kiss I, Ember I, Kozma L. Oncogene amplification and overexpression of oncoproteins in thyroid papillary cancer. In Vivo. 2005;19(2):465–70. 44. Romano MI, Grattone M, Karner MP, Moiguer S, Tetelbaum F, Romano LA, Illescas E, Padin R, Cueva F, Burdman JA. Relationship between the level of cMYC mRNA and histologic aggressiveness in thyroid tumors. Horm Res. 1993;39(3-4):161–5.

Submit your next manuscript to BioMed Central and we will help you at every step: • We accept pre-submission inquiries • Our selector tool helps you to find the most relevant journal • We provide round the clock customer support • Convenient online submission • Thorough peer review • Inclusion in PubMed and all major indexing services • Maximum visibility for your research Submit your manuscript at www.biomedcentral.com/submit